Merck is undergoing a strategic restructuring, resulting in immediate job cuts in administration, sales, and research as part of a plan to save $3 billion by 2027.

The company recently completed a massive expansion in Durham and is acquiring a Raleigh company for billions. Join us as we honor outstanding C-Level Executives for their invaluable contributions to ...

The program was formally launched July 28 at a signing ceremony at Wake Tech’s Beltline Education Center in Raleigh. Leaders ...

Biogen said it intends to invest an additional $2 billion to expand operations at its largest manufacturing facilities within North Carolina’s Research Triangle Park (RTP).

The drugmaker has invested $10 billion in Wake and Durham counties over the past 30 years. Biogen says that figure will ...

Trump has rolled back many of his steepest tariffs over recent months, including a sky-high levy on China, the top source of ...

Verona Pharma's flagship drug last year became the first new maintenance treatment for chronic obstructive pulmonary disease in more than a decade.

Merck’s potential for upside hinges on its ability to execute on several key fronts: successfully advancing its pipeline, expanding geographically, and making strategic acquisitions.

In this analysis, we explore the potential upside for Merck despite its short-term hurdles.

Merck has received approval from the Food and Drug Administration to expand use of its blockbuster drug, Keytruda, to treat head and neck cancers.

Merck & Co. won US approval for a shot that protects against RSV, the most common cause of hospitalization among infants.